0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Galectin-1

Galectin-1

Brief Information

Name:Galectin-1
Target Synonym:Epididymis Secretory Sperm Binding Protein,Putative MAPK-activating protein PM12,Galectin-1,HBL,LGALS1,Lectin, Galactoside-Binding, Soluble, 1,Beta-Galactoside-Binding Lectin L-14-I,14 KDa Laminin-Binding Protein,S-Lac Lectin 1,14 KDa Lectin,Galaptin,HLBP
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GA1-H4113 Human Human Galectin-1 / LGALS1 Protein, Tag Free (MALS verified)
GA1-H4113-structure
GA1-H4113-sds

Part of Bioactivity data

GA1-H4113-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human CD45, His,Avitag (Cat. No. CD5-H82E7) on SA Biosensor, can bind Human Galectin-1, Tag Free (Cat. No. GA1-H4113) with an affinity constant of 2.0 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

GA1-H4113-MALS-HPLC
Human Galectin-1, Tag Free (Cat. No. ) MALS images

The purity of Human Galectin-1, Tag Free (Cat. No. GA1-H4113) was more than 90% and the molecular weight of this protein is around 25-35 kDa verified by SEC-MALS.

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human CD45, His,Avitag (Cat. No. CD5-H82E7) on SA Biosensor, can bind Human Galectin-1, Tag Free (Cat. No. GA1-H4113) with an affinity constant of 2.0 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

LGALS1,GAL1,GBP,Galectin-1,DKFZp686E23103

Background

Galectin-1 (Gal-1), a member of the β-galactoside-binding animal lectin family, has a wide range of biological activities, which makes it an attractive target for medical applications. Gal-1 is ubiquitously but differentially expressed in normal and pathological animal tissues, and a variety of biological activities, including modulation of innate and adaptive immune responses, malignant progression of tumor cells, etc.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ocriplasmin A-01016; THR-409 Approved Thrombogenics Jetrea, Jejetrea EU Retinal Diseases null 2012-10-17 Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Tissue Adhesions; Retinal Diseases; Stroke; Diabetic macular oedema; Eye Diseases; Symptomatic Vitreomacular Adhesion; Venous Thrombosis; Macular Degeneration; Diabetic Retinopathy Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TD-139 TD-139 Phase 2 Clinical The University Of Edinburgh, Lund University Foundation Idiopathic Pulmonary Fibrosis Details

This web search service is supported by Google Inc.

totop